<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1244">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04800588</url>
  </required_header>
  <id_info>
    <org_study_id>4R44AG062076</org_study_id>
    <nct_id>NCT04800588</nct_id>
  </id_info>
  <brief_title>Computerized Tests of Cognitive Decline in Presymptomatic Alzheimer's Disease</brief_title>
  <official_title>Computerized Tests of Cognitive Decline in Presymptomatic Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurobehavioral Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Neurobehavioral Systems, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will study performance on computerized cognitive tasks in healthy&#xD;
      participants of different ages to gather normative data for newly developed computerized&#xD;
      cognitive tests. These tests are designed to permit the early detection of individuals at&#xD;
      risk of age-related cognitive decline.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Group A, the investigators will evaluate the performance of healthy older participants (N&#xD;
      = 500, age range 60 to 89 years) for three days at enrollment and then at 6-month intervals&#xD;
      for three years thereafter. The goal is to characterize changes in performance to aging and&#xD;
      task experience in a group of older subjects. Subjects will also undergo APOE genetic testing&#xD;
      with saliva samples.&#xD;
&#xD;
      In Group B, the investigators will compare the performance of normal participants (N = 100,&#xD;
      age range 18 to 89) on computerized and manually administered cognitive tasks.&#xD;
&#xD;
      In Group C, the investigators will gather normative data from younger participants (N = 400,&#xD;
      ages 18 to 59) for three days at enrollment. A subset of these subjects (N=150) will undergo&#xD;
      longitudinal testing at 6-month intervals for three years thereafter.&#xD;
&#xD;
      In Group D, the investigators will examine the performance of participants (N=1000, ages 18&#xD;
      to 89) on a 30-min computerized cognitive screening test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Longitudinal normative data collection from healthy participants</measure>
    <time_frame>Longitudinal testing at six-month intervals</time_frame>
    <description>Multiple behavioral outcome measures will be obtained from each cognitive test including measures of response time (in milliseconds) and accuracy (in percent correct). Recordings of subject's verbal responses will also be analyzed phonologically and automatically transcribed to permit the lexical, syntactic, and semantic analysis of speech output. Researchers will also obtain saliva samples of DNA from participants 60 years of age and older and analyze them for the presence of the APOE epsilon 4 variant. Questionnaire data will be used to identify factors that may influence performance on the cognitive tests. The primary outcome measures are the scores obtained during enrollment testing that predict a decline in longitudinal performance.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Cognitive Decline</condition>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Older participant group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>We will evaluate the performance of healthy older participants (N = 500, age range 60 to 89 years) for three days at enrollment and then at 6-month intervals for three years thereafter. The goal is to characterize changes in performance to aging and task experience in a group of older subjects. Subjects will undergo APOE genetic testing with saliva samples.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CCAB vs. manual test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>We will compare the performance of normal participants (N = 100, age range 18 to 89) on computerized and manually administered cognitive tasks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Younger participant group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>We will gather normative data from younger participants (N = 400, ages 18 to 59) for three days at enrollment. A subset of these subjects (N=150) will undergo longitudinal testing at 6-month intervals for three years thereafter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Screening test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>We will examine the performance of participants (N=1000, ages 18 to 89) on a 30-min computerized cognitive screening test. Testing may be repeated at 6-month or 1-year intervals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>California Cognitive Assessment Battery</intervention_name>
    <description>The California Cognitive Assessment Battery (CCAB) is a collection of computerized cognitive tests that will be telemedically administered to participants in their homes using a tablet computer and accessories provided by the research team. Testing may also occur in research laboratories. Previous versions of CCAB tests have been described in 16 manuscripts which describe (a) the psychometric characteristics of normative data collected in large participant populations (300 to 2,300 subjects for different tests) and (b) the sensitivity of CCAB tests for detecting performance abnormalities in patients with traumatic brain injury (TBI) and in control participants simulating the cognitive deficits that follow mild TBI.</description>
    <arm_group_label>CCAB vs. manual test group</arm_group_label>
    <arm_group_label>Older participant group</arm_group_label>
    <arm_group_label>Younger participant group</arm_group_label>
    <other_name>CCAB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Fast Automated Cognitive Test Battery</intervention_name>
    <description>The Fast Automated Cognitive Test Battery (FACT-B) is a condensed selection of computerized cognitive tests drawn from the CCAB to act as a screening tool. These tests will be telemedically administered to participants in their homes using a tablet computer and accessories provided by the research team. Testing may also occur in research laboratories.</description>
    <arm_group_label>Screening test group</arm_group_label>
    <other_name>FACTB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be able to use computer mouse and touch screen.&#xD;
&#xD;
          -  Must speak English as a primary language&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of psychiatric disorder&#xD;
&#xD;
          -  History of stroke or transient ischemic attack&#xD;
&#xD;
          -  History of substance abuse&#xD;
&#xD;
          -  History of medical or sensory disorders that are incompatible with effective testing&#xD;
&#xD;
          -  History of traumatic brain injury with hospitalization and extended loss of&#xD;
             consciousness&#xD;
&#xD;
          -  History of epilepsy&#xD;
&#xD;
          -  History of depression or anxiety&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>John M Wyma-Hughes</last_name>
    <phone>5105279231</phone>
    <email>clinical_trial_coordinator@neurobs.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Woods</last_name>
    <phone>5105279231</phone>
    <email>drdlwoods@neurobs.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Neurobehavioral Systems, Inc.</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Garret Williams, BS</last_name>
      <phone>510-527-9231</phone>
      <email>garrett_williams@neurobs.com</email>
    </contact>
    <contact_backup>
      <last_name>John Wyma-Hughes, JD</last_name>
      <phone>5105279231</phone>
      <email>clinical_trial_coordinator@neurobs.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Woods DL, Kishiyamaa MM, Lund EW, Herron TJ, Edwards B, Poliva O, Hink RF, Reed B. Improving digit span assessment of short-term verbal memory. J Clin Exp Neuropsychol. 2011 Jan;33(1):101-11. doi: 10.1080/13803395.2010.493149.</citation>
    <PMID>20680884</PMID>
  </reference>
  <reference>
    <citation>Woods DL, Herron TJ, Yund EW, Hink RF, Kishiyama MM, Reed B. Computerized analysis of error patterns in digit span recall. J Clin Exp Neuropsychol. 2011 Aug;33(7):721-34. doi: 10.1080/13803395.2010.550602.</citation>
    <PMID>21957866</PMID>
  </reference>
  <reference>
    <citation>Woods DL, Wyma JM, Herron TJ, Yund EW. The Effects of Repeat Testing, Malingering, and Traumatic Brain Injury on Computerized Measures of Visuospatial Memory Span. Front Hum Neurosci. 2016 Jan 5;9:690. doi: 10.3389/fnhum.2015.00690. eCollection 2015.</citation>
    <PMID>26779001</PMID>
  </reference>
  <reference>
    <citation>Woods DL, Wyma JM, Herron TJ, Yund EW. An improved spatial span test of visuospatial memory. Memory. 2016 Sep;24(8):1142-55. doi: 10.1080/09658211.2015.1076849. Epub 2015 Sep 11.</citation>
    <PMID>26357906</PMID>
  </reference>
  <reference>
    <citation>Woods DL, Wyma JM, Herron TJ, Yund EW. The Bay Area Verbal Learning Test (BAVLT): Normative Data and the Effects of Repeated Testing, Simulated Malingering, and Traumatic Brain Injury. Front Hum Neurosci. 2017 Jan 12;10:654. doi: 10.3389/fnhum.2016.00654. eCollection 2016.</citation>
    <PMID>28127280</PMID>
  </reference>
  <reference>
    <citation>Woods DL, Wyma JM, Herron TJ, Yund EW, Reed B. The Dyad-Adaptive Paced Auditory Serial Addition Test (DA-PASAT): Normative data and the effects of repeated testing, simulated malingering, and traumatic brain injury. PLoS One. 2018 Apr 20;13(4):e0178148. doi: 10.1371/journal.pone.0178148. eCollection 2018.</citation>
    <PMID>29677192</PMID>
  </reference>
  <reference>
    <citation>Woods DL, Wyma JM, Herron TJ, Yund EW. The Effects of Aging, Malingering, and Traumatic Brain Injury on Computerized Trail-Making Test Performance. PLoS One. 2015 Jun 10;10(6):e0124345. doi: 10.1371/journal.pone.0124345. eCollection 2015.</citation>
    <PMID>26060999</PMID>
  </reference>
  <reference>
    <citation>Woods DL, Wyma JM, Yund EW, Herron TJ, Reed B. Factors influencing the latency of simple reaction time. Front Hum Neurosci. 2015 Mar 26;9:131. doi: 10.3389/fnhum.2015.00131. eCollection 2015.</citation>
    <PMID>25859198</PMID>
  </reference>
  <reference>
    <citation>Woods DL, Wyma JM, Yund EW, Herron TJ. The Effects of Repeated Testing, Simulated Malingering, and Traumatic Brain Injury on High-Precision Measures of Simple Visual Reaction Time. Front Hum Neurosci. 2015 Nov 9;9:540. doi: 10.3389/fnhum.2015.00540. eCollection 2015.</citation>
    <PMID>26617505</PMID>
  </reference>
  <reference>
    <citation>Hubel KA, Reed B, Yund EW, Herron TJ, Woods DL. Computerized measures of finger tapping: effects of hand dominance, age, and sex. Percept Mot Skills. 2013 Jun;116(3):929-52.</citation>
    <PMID>24175464</PMID>
  </reference>
  <reference>
    <citation>Hubel KA, Yund EW, Herron TJ, Woods DL. Computerized measures of finger tapping: reliability, malingering and traumatic brain injury. J Clin Exp Neuropsychol. 2013;35(7):745-58. doi: 10.1080/13803395.2013.824070. Epub 2013 Aug 15.</citation>
    <PMID>23947782</PMID>
  </reference>
  <reference>
    <citation>Woods DL, Wyma JM, Yund EW, Herron TJ. The Effects of Repeated Testing, Simulated Malingering, and Traumatic Brain Injury on Visual Choice Reaction Time. Front Hum Neurosci. 2015 Nov 24;9:595. doi: 10.3389/fnhum.2015.00595. eCollection 2015.</citation>
    <PMID>26635569</PMID>
  </reference>
  <reference>
    <citation>Woods DL, Wyma JM, Yund EW, Herron TJ, Reed B. Age-related slowing of response selection and production in a visual choice reaction time task. Front Hum Neurosci. 2015 Apr 23;9:193. doi: 10.3389/fnhum.2015.00193. eCollection 2015. Erratum in: Front Hum Neurosci. 2015;9:350.</citation>
    <PMID>25954175</PMID>
  </reference>
  <reference>
    <citation>Woods DL, Wyma JM, Herron TJ, Yund EW. Computerized Analysis of Verbal Fluency: Normative Data and the Effects of Repeated Testing, Simulated Malingering, and Traumatic Brain Injury. PLoS One. 2016 Dec 9;11(12):e0166439. doi: 10.1371/journal.pone.0166439. eCollection 2016.</citation>
    <PMID>27936001</PMID>
  </reference>
  <reference>
    <citation>Woods DL, Wyma JM, Herron TJ, Yund EW. A Computerized Test of Design Fluency. PLoS One. 2016 May 3;11(5):e0153952. doi: 10.1371/journal.pone.0153952. eCollection 2016. Erratum in: PLoS One. 2016;11(7):e0158933.</citation>
    <PMID>27138985</PMID>
  </reference>
  <reference>
    <citation>Woods DL, Yund EW, Wyma JM, Ruff R, Herron TJ. Measuring executive function in control subjects and TBI patients with question completion time (QCT). Front Hum Neurosci. 2015 May 19;9:288. doi: 10.3389/fnhum.2015.00288. eCollection 2015.</citation>
    <PMID>26042021</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aging</keyword>
  <keyword>Elderly</keyword>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Cognition</keyword>
  <keyword>Computerized</keyword>
  <keyword>Testing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

